CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ÀüÈ«Àç
  • ¾Ï¼¾ÅÍÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °£¾Ï/Ãé´ãµµ¾Ï
  • Á÷ À§: ºÎ±³¼ö(¾Ï¼¾ÅÍÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

µî·Ï

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ ´Ù¿î·Îµå
45 ÇØ¿Ü Oral presentation on ¡°BIM deletion polymorphism as a biomarker in advanced gastric cancer¡± (Japanese Gastric Cancer Association for Clinical Oncology Meeting, Osaka, Japan, 2013)  
44 ÇØ¿Ü Oral presentation on ¡°A phase IB/II Trial of FGF trap and paclitaxel combination treatment in patient with advanced gastric cancer¡± (KCSG Methodology Workshop, Seoul, Korea, 2014) Award for outstanding presentation  
43 ÇØ¿Ü Oral presentation on ¡°The Clinicopathological Features and Prognostic Impact of ALK-positivity in Resected Gastric Cancer Patients¡± (Global Academic Program 2014 Conference)  
42 ÇØ¿Ü Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer (ASCO Annual Meeting, Chicago, United States, 2015)  
41 ÇØ¿Ü Randomized phase II trial comparing 4 doublets as a front-line treatment in Asian patients with recurrent/metastatic gastric cancer (ASCO Annual Meeting, Chicago, United States, 2016)  
40 ÇØ¿Ü Adjuvant chemotherapy in gastric cancer (The 17th Clinical Trial Education Workshop, Seoul, Korea, 2017)  
39 ÇØ¿Ü Adjuvant Treatment of pancreatic cancer (KCSG, Hepatobiliary & pancreatic cancer symposium, Seoul, Korea, 2017)  
38 ÇØ¿Ü STING agonist modulates tumor immune microenvironment of NSCLC to potentiate the efficacy of PD-1 immune checkpoint blockade (CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Mainz/Frankfurt, Germany, 2017)  
37 ÇØ¿Ü Oncolytic virotherapy with JX-594 (Pexa-Vec) modulates tumor immune microenvironment to potentiate the efficacy of immune checkpoint blockade (Keystone symposia, Montreal, Canada, 2018)  
36 ÇØ¿Ü Combination of oncolytic vaccinia virus and immune checkpoint blockade overcomes resistance to immunotherapy in renal cell carcinoma (AACR Annual Meeting, Chicago, United States, 2018)  
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729